May 2024
1. BURKI T
   EPA ruling to ban chrysotile asbestos.
   Lancet Oncol. 2024;25:537.
   

   >> Share

   
   April 2024
2. SMIT EF, Felip E, Uprety D, Nagasaka M, et al
   Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
   Lancet Oncol. 2024;25:439-454.
   

   >> Share

   
   March 2024
3. GOULART BHL, Mushti SL, Chatterjee S, Larkins E, et al
   Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis.
   Lancet Oncol. 2024 Mar 5:S1470-2045(24)00040.
   

   >> Share

   
   February 2024
4. RHA SY, Bordia S
   Pembrolizumab plus chemotherapy for advanced gastric cancer - Authors' reply.
   Lancet Oncol. 2024;25:e52.
   

   >> Share

   
   
5. SCHUTTE T, Derks S, van Laarhoven HWM
   Pembrolizumab plus chemotherapy for advanced gastric cancer.
   Lancet Oncol. 2024;25:e51.
   

   >> Share

   
   
6. HUANG CY, Wu XB
   Pembrolizumab plus chemotherapy for advanced gastric cancer.
   Lancet Oncol. 2024;25:e50.
   

   >> Share

   
   January 2024
7. RASHID T, Bennett JE, Muller DC, Cross AJ, et al
   Mortality from leading cancers in districts of England from 2002 to 2019: a population-based, spatiotemporal study.
   Lancet Oncol. 2024;25:86-98.
   

   >> Share

   
   December 2023
8. LEAL T, Langer C
   Tumor Treating Fields therapy in metastatic non-small-cell lung cancer - Authors' reply.
   Lancet Oncol. 2023;24:e454.
   

   >> Share

   
   
9. OLIVIER T, Addeo A
   Tumor Treating Fields therapy in metastatic non-small-cell lung cancer.
   Lancet Oncol. 2023;24:e453.
   

   >> Share

   
   
10. FURLOW B
    IASLC calls for clinical trials to use tobacco use data.
    Lancet Oncol. 2023;24:1309.
    

    >> Share

    
    November 2023
11. SCOTT SE, Gildea C, Nicholson BD, Evans RE, et al
    Future cancer risk after urgent suspected cancer referral in England when cancer is not found: a national cohort study.
    Lancet Oncol. 2023;24:1242-1251.
    

    >> Share

    
    
12. DOUMA LH, Lalezari F, van der Noort V, de Vries JF, et al
    Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.
    Lancet Oncol. 2023;24:1219-1228.
    

    >> Share

    
    October 2023
13. COOPER WA
    Lessons and opportunities from improved understanding of global lung cancer histological subtypes.
    Lancet Oncol. 2023 Oct 11:S1470-2045(23)00475.
    

    >> Share

    
    
14. ZHANG Y, Vaccarella S, Morgan E, Li M, et al
    Global variations in lung cancer incidence by histological subtype in 2020: a population-based study.
    Lancet Oncol. 2023 Oct 11:S1470-2045(23)00444.
    

    >> Share

    
    
15. HU X, Wang C, Huang W, Barber SM, et al
    Pembrolizumab monotherapy for advanced chordoma.
    Lancet Oncol. 2023;24:e399.
    

    >> Share

    
    September 2023
16. FENNELL DA
    Tumor Treating Fields therapy could potentiate immunotherapy in non-small-cell lung cancer.
    Lancet Oncol. 2023;24:946-947.
    

    >> Share

    
    
17. LEAL T, Kotecha R, Ramlau R, Zhang L, et al
    Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 st
    Lancet Oncol. 2023;24:1002-1017.
    

    >> Share

    
    August 2023
18. OZGUROGLU M, Kilickap S, Sezer A, Gumus M, et al
    First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 tri
    Lancet Oncol. 2023 Aug 14:S1470-2045(23)00329.
    

    >> Share

    
    
19. GOURD E
    Middle-age lung screening for everyone who has smoked.
    Lancet Oncol. 2023;24:838.
    

    >> Share

    
    July 2023
20. JAYAKRISHNAN B, Burney I, Osman AH, Bennji SM, et al
    Adenocarcinoma of lung presenting as diffuse interstitial lung disease.
    Lancet Oncol. 2023;24:e323.
    

    >> Share

    
    May 2023
21. O'DOWD EL, Lee RW, Akram AR, Bartlett EC, et al
    Defining the road map to a UK national lung cancer screening programme.
    Lancet Oncol. 2023;24:e207-e218.
    

    >> Share

    
    
22. GHORANI E, Quartagno M, Blackhall F, Gilbert DC, et al
    REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment.
    Lancet Oncol. 2023;24:e219-e227.
    

    >> Share

    
    March 2023
23. MITTAL R, Maikap D, Mishra P, Padhan P, et al
    Sclerotic bone metastasis as initial manifestation of lung adenocarcinoma in a patient with SLE.
    Lancet Oncol. 2023;24:e144.
    

    >> Share

    
    February 2023
24. DONG YM, Sun SZ, Ding SS, Chen HM, et al
    Pseudoprogression of a cutaneous lung cancer metastasis.
    Lancet Oncol. 2023;24:e102.
    

    >> Share

    
    December 2022
25. SORSCHER S
    Pembrolizumab as adjuvant therapy in non-small-cell lung cancer.
    Lancet Oncol. 2022;23:e529.
    

    >> Share

    
    
26. GANGULY S, Gogia A
    Pembrolizumab as adjuvant therapy in non-small-cell lung cancer.
    Lancet Oncol. 2022;23:e528.
    

    >> Share

    
    
27. UPRETY D
    Pembrolizumab as adjuvant therapy in non-small-cell lung cancer.
    Lancet Oncol. 2022;23:e527.
    

    >> Share

    
    November 2022
28. WESTEEL V, Zalcman G, Scherpereel A, Milleron B, et al
    Thoracic CT follow-up after non-small-cell lung cancer resection - Authors' reply.
    Lancet Oncol. 2022;23:e486.
    

    >> Share

    
    
29. GOTO T
    Thoracic CT follow-up after non-small-cell lung cancer resection.
    Lancet Oncol. 2022;23:e485.
    

    >> Share

    
    
30. WOODARD GA, Boffa DJ, Blasberg JD
    Thoracic CT follow-up after non-small-cell lung cancer resection.
    Lancet Oncol. 2022;23:e484.
    

    >> Share

    
    
31. HEUVELMANS MA, Oudkerk M
    Thoracic CT follow-up after non-small-cell lung cancer resection.
    Lancet Oncol. 2022;23:e483.
    

    >> Share

    
    October 2022
32. QIN N, Wang C, Chen C, Yang L, et al
    Association of the interaction between mosaic chromosomal alterations and polygenic risk score with the risk of lung cancer: an array-based case-control association and prospective cohort study.
    Lancet Oncol. 2022 Oct 17. pii: S1470-2045(22)00600.
    

    >> Share

    
    
33. SUBBIAH V, Wolf J, Konda B, Kang H, et al
    Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
    Lancet Oncol. 2022;23:1261-1273.
    

    >> Share

    
    September 2022
34. GOURD E
    New evidence that air pollution contributes substantially to lung cancer.
    Lancet Oncol. 2022 Sep 15. pii: S1470-2045(22)00569.
    

    >> Share

    
    
35. O'BRIEN M, Paz-Ares L, Marreaud S, Dafni U, et al
    Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
    Lancet Oncol. 2022 Sep 9. pii: S1470-2045(22)00518.
    

    >> Share

    
    August 2022
36. WESTEEL V, Foucher P, Scherpereel A, Domas J, et al
    Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2022 Aug 11. pii: S1470-2045(22)00451.
    

    >> Share

    
    
37. NESTLE U, Delorme S
    What is the best choice of follow-up procedure following resection of lung cancer?
    Lancet Oncol. 2022 Aug 11. pii: S1470-2045(22)00499.
    

    >> Share

    
    
38. GERALDES FO
    IASLC 2022 World Conference on Lung Cancer.
    Lancet Oncol. 2022 Aug 11. pii: S1470-2045(22)00510.
    

    >> Share

    
    July 2022
39. ELKRIEF A, Yu H
    Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed?
    Lancet Oncol. 2022 Jul 28. pii: S1470-2045(22)00449.
    

    >> Share

    
    
40. LU S, Wu L, Jian H, Chen Y, et al
    Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double
    Lancet Oncol. 2022 Jul 28. pii: S1470-2045(22)00382.
    

    >> Share

    
    
41. SILVA V, Abrao F, Peres S, Rosamilia G, et al
    Prognostic factors in curative intent stage I lung adenocarcinoma: a retrospective hospital-based cohort study.
    Lancet Oncol. 2022;23 Suppl 1:S31.
    

    >> Share

    
    
42. LAYCOCK A, Taylor O, Boardman G, Bentel J, et al
    Discordance between clinical and post-surgical staging of patients with operable non-small cell lung cancer: a retrospective audit of lung cancer surgery with curative intent from a single pathology practice.
    Lancet Oncol. 2022;23 Suppl 1:S24.
    

    >> Share

    
    
43. ZHENG X, Lu T, Wu S, Peng W, et al
    Tumour response heterogeneity as a powerful independent predictor of treatment outcome in advanced lung adenocarcinoma: a retrospective analysis.
    Lancet Oncol. 2022;23 Suppl 1:S13.
    

    >> Share

    
    June 2022
44. RECONDO G, Mezquita L
    Tiragolumab and atezolizumab in patients with PD-L1 positive non-small-cell lung cancer.
    Lancet Oncol. 2022;23:695-697.
    

    >> Share

    
    
45. ANDRE T, Diaz LA Jr, Shiu KK
    Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy - Authors' reply.
    Lancet Oncol. 2022;23:e246.
    

    >> Share

    
    
46. BOMZE D, Mutti L, Goldman A, Markel G, et al
    Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy.
    Lancet Oncol. 2022;23:e245.
    

    >> Share

    
    
47. FENNELL DA, Nusrat N
    Abemaciclib for malignant pleural mesothelioma - Authors' reply.
    Lancet Oncol. 2022;23:e238.
    

    >> Share

    
    
48. NARDONE V, Porta C, Giannicola R, Correale P, et al
    Abemaciclib for malignant pleural mesothelioma.
    Lancet Oncol. 2022;23:e237.
    

    >> Share

    
    
49. ZAUDERER MG, Szlosarek PW, Le Moulec S, Popat S, et al
    EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
    Lancet Oncol. 2022;23:758-767.
    

    >> Share

    
    May 2022
50. GAEBE K, Li AY, Park A, Parmar A, et al
    Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis.
    Lancet Oncol. 2022 May 26. pii: S1470-2045(22)00271.
    

    >> Share

    
    
51. RIEKEN S
    Stereotactic radiosurgery for patients with small-cell lung cancer brain metastases.
    Lancet Oncol. 2022 May 26. pii: S1470-2045(22)00301.
    

    >> Share

    
    
52. SMITH KER, Mansfield AS
    Validating chemoimmunotherapy in small-cell lung cancer.
    Lancet Oncol. 2022 May 13. pii: S1470-2045(22)00288.
    

    >> Share

    
    
53. CHO BC, Abreu DR, Hussein M, Cobo M, et al
    Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
    Lancet Oncol. 2022 May 13. pii: S1470-2045(22)00226.
    

    >> Share

    
    
54. WANG J, Zhou C, Yao W, Wang Q, et al
    Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2022 May 13. pii: S1470-2045(22)00224.
    

    >> Share

    
    April 2022
55. WU YL
    Sequential chemoradiotherapy followed by sugemalimab for locally advanced NSCLC - Author's reply.
    Lancet Oncol. 2022;23:e159.
    

    >> Share

    
    
56. BI N, Wang Y, Wang L
    Sequential chemoradiotherapy followed by sugemalimab for locally advanced NSCLC.
    Lancet Oncol. 2022;23:e158.
    

    >> Share

    
    
57. OCHOA-DE-OLZA M, Bourhis J, Coukos G, Herrera FG, et al
    Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.
    Lancet Oncol. 2022;23:e157.
    

    >> Share

    
    
58. CHANG JY, Verma V, Welsh JW, Formenti SC, et al
    Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.
    Lancet Oncol. 2022;23:e156.
    

    >> Share

    
    
59. KINDLER HL, Novello S, Bearz A, Ceresoli GL, et al
    Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
    Lancet Oncol. 2022;23:540-552.
    

    >> Share

    
    
60. OTTAIANO A, Santorsola M, Caraco F, Caraglia M, et al
    Initial tumour burden and hidden oligometastatic disease in phase 3 clinical trials.
    Lancet Oncol. 2022;23:452-454.
    

    >> Share

    
    
61. ZAUDERER MG, Offin M
    ARCS-M: forging progress from this negative trial in malignant pleural mesothelioma.
    Lancet Oncol. 2022;23:445-446.
    

    >> Share

    
    March 2022
62. FENNELL DA, King A, Mohammed S, Greystoke A, et al
    Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
    Lancet Oncol. 2022;23:374-381.
    

    >> Share

    
    February 2022
63. MACMANUS M, Hegi-Johnson F
    Overcoming immunotherapy resistance in NSCLC.
    Lancet Oncol. 2022;23:191-193.
    

    >> Share

    
    January 2022
64. ZHOU C, Wang Z, Sun Y, Cao L, et al
    Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
    Lancet Oncol. 2022 Jan 14. pii: S1470-2045(21)00650.
    

    >> Share

    
    
65. ROSELL R, Cao P
    Promising outlook with sugemalimab in non-small-cell lung cancer.
    Lancet Oncol. 2022 Jan 14. pii: S1470-2045(21)00698.
    

    >> Share

    
    
66. ZHOU Q, Chen M, Jiang O, Pan Y, et al
    Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phas
    Lancet Oncol. 2022 Jan 14. pii: S1470-2045(21)00630.
    

    >> Share

    
    
67. SCHOENFELD JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, et al
    Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
    Lancet Oncol. 2022 Jan 13. pii: S1470-2045(21)00658.
    

    >> Share

    
    
68. FENNELL DA, Griffiths G, Ottensmeier C, Hanna GG, et al
    CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply.
    Lancet Oncol. 2022;23:e14-e15.
    

    >> Share

    
    
69. CORREALE P, Pentimalli F, Nardone V, Giordano A, et al
    CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma?
    Lancet Oncol. 2022;23:e13.
    

    >> Share

    
    December 2021
70. LE PECHOUX C, Pourel N, Barlesi F, Lerouge D, et al
    Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.
    Lancet Oncol. 2021 Dec 14. pii: S1470-2045(21)00606.
    

    >> Share

    
    
71. HENDRIKS LEL, De Ruysscher DKM
    Postoperative radiotherapy in resected N2 non-small-cell lung cancer: Lung ART.
    Lancet Oncol. 2021 Dec 14. pii: S1470-2045(21)00654.
    

    >> Share

    
    
72. PFEIFFER P, Qvortrup C
    KRAS(G12C) inhibition in colorectal cancer.
    Lancet Oncol. 2021 Dec 14. pii: S1470-2045(21)00652.
    

    >> Share

    
    
73. TAMMEMAGI MC, Ruparel M, Tremblay A, Myers R, et al
    USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study.
    Lancet Oncol. 2021 Dec 10. pii: S1470-2045(21)00590.
    

    >> Share

    
    
74. TEN HAAF K
    Risk-based lung cancer screening eligibility criteria: towards implementation.
    Lancet Oncol. 2021 Dec 10. pii: S1470-2045(21)00636.
    

    >> Share

    
    
75. WILKINSON E
    COVID-19 pandemic to lead to thousands of additional UK lung cancer deaths.
    Lancet Oncol. 2021 Dec 2. pii: S1470-2045(21)00699.
    

    >> Share

    
    
76. CHANG JY, Verma V, Feng L, Roth JA, et al
    SABR for operable stage I non-small-cell lung cancer: comparison to surgery - Authors' reply.
    Lancet Oncol. 2021;22:e537-e538.
    

    >> Share

    
    
77. ZHANG J, Liu L, Zhao K, Guo C, et al
    SABR for operable stage I non-small-cell lung cancer: comparison to surgery.
    Lancet Oncol. 2021;22:e536.
    

    >> Share

    
    
78. LUO MS
    SABR for operable stage I non-small-cell lung cancer: comparison to surgery.
    Lancet Oncol. 2021;22:e535.
    

    >> Share

    
    
79. KASHIHARA T
    SABR for operable stage I non-small-cell lung cancer: comparison to surgery.
    Lancet Oncol. 2021;22:e534.
    

    >> Share

    
    
80. ZUCALI PA, Pinto C, Ceresoli GL
    RAMES study: is there really a role for VEGF inhibition in mesothelioma? - Authors' reply.
    Lancet Oncol. 2021;22:e533.
    

    >> Share

    
    
81. PORTA C, Nardone V, Gray SG, Correale P, et al
    RAMES study: is there really a role for VEGF inhibition in mesothelioma?
    Lancet Oncol. 2021;22:e532.
    

    >> Share

    
    November 2021
82. SAW SPL, Ong BH, Chua KLM, Takano A, et al
    Revisiting neoadjuvant therapy in non-small-cell lung cancer.
    Lancet Oncol. 2021;22:e501-e516.
    

    >> Share

    
    
83. FENNELL DA, Ewings S, Ottensmeier C, Califano R, et al
    Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
    Lancet Oncol. 2021;22:1530-1540.
    

    >> Share

    
    October 2021
84. KINDLER HL
    Understanding the new therapeutic options for mesothelioma.
    Lancet Oncol. 2021;22:1353-1355.
    

    >> Share

    
    
85. PINTO C, Zucali PA, Pagano M, Grosso F, et al
    Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Oncol. 2021;22:1438-1447.
    

    >> Share

    
    September 2021
86. LANDMAN A
    2021 World Conference on Lung Cancer.
    Lancet Oncol. 2021 Sep 16. pii: S1470-2045(21)00547.
    

    >> Share

    
    
87. CHANG JY, Mehran RJ, Feng L, Verma V, et al
    Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
    Lancet Oncol. 2021 Sep 13. pii: S1470-2045(21)00401.
    

    >> Share

    
    
88. LOUIE AV, Tjong MC, Siva S
    Surgery versus SABR for early-stage lung cancer-time to call it a draw?
    Lancet Oncol. 2021 Sep 13. pii: S1470-2045(21)00457.
    

    >> Share

    
    
89. BURKI TK
    Developments in lung cancer biology in never-smokers.
    Lancet Oncol. 2021 Sep 9. pii: S1470-2045(21)00532.
    

    >> Share

    
    August 2021
90. HUYNH C, Sorin M, Rayes R, Fiset PO, et al
    Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer.
    Lancet Oncol. 2021;22:1056-1058.
    

    >> Share

    
    June 2021
91. GAINOR JF, Curigliano G, Kim DW, Lee DH, et al
    Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
    Lancet Oncol. 2021 Jun 9. pii: S1470-2045(21)00247.
    

    >> Share

    
    
92. GRONBERG BH, Langer SW, Nyman J, Halvorsen TO, et al
    Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2021;22:e222.
    

    >> Share

    
    
93. XIE L, Fan X, Qian B
    Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer.
    Lancet Oncol. 2021;22:e221.
    

    >> Share

    
    
94. LEVY A, Le Pechoux C, Faivre-Finn C
    Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer.
    Lancet Oncol. 2021;22:e220.
    

    >> Share

    
    May 2021
95. ALTORKI NK, McGraw TE, Borczuk AC, Saxena A, et al
    Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
    Lancet Oncol. 2021 May 17. pii: S1470-2045(21)00149.
    

    >> Share

    
    
96. SEPESI B, Cascone T
    Will radiotherapy be a future part of neoadjuvant therapy in operable non-small-cell lung cancer?
    Lancet Oncol. 2021 May 17. pii: S1470-2045(21)00261.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share